Sana Biotechnology, Inc. Investing Cash Flow
Sana Biotechnology, Inc. (SANA) reported Investing Cash Flow of -$38.08 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-10
- Sana Biotechnology, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was -$87.52M, a 1239.57% decline year-over-year.
- Sana Biotechnology, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was $49.44M, a 197.76% increase year-over-year.
- Sana Biotechnology, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was -$16.50M, a 135.03% decline year-over-year.
- Sana Biotechnology, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was -$48.02M, a 214.96% decline year-over-year.
- Sana Biotechnology, Inc. net cash provided by (used in) investing activities for fiscal 2025 was -$40.24M, a 330.55% decline from fiscal 2024.
- Sana Biotechnology, Inc. net cash provided by (used in) investing activities for fiscal 2024 was $17.45M, a 89.85% decline from fiscal 2023.
- Sana Biotechnology, Inc. net cash provided by (used in) investing activities for fiscal 2023 was $172.01M, a 18.31% decline from fiscal 2022.
- Sana Biotechnology, Inc. net cash provided by (used in) investing activities for fiscal 2022 was $210.56M.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$87.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$38.08M 10-Q · filed 2026-08-10 | -$54.58M derived: sum of 3 quarters · filed 2026-08-10 | -$102.60M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $49.44M 10-Q · filed 2026-05-11 | $32.94M derived: sum of 2 quarters · filed 2026-05-11 | -$15.08M derived: sum of 3 quarters · filed 2026-05-11 | -$7.40M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | -$16.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$64.52M derived: sum of 2 quarters · filed 2026-03-03 | -$56.84M derived: sum of 3 quarters · filed 2026-08-10 | -$40.24M 10-K · filed 2026-03-03 |
| 2025-09-30 | -$48.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$40.34M derived: sum of 2 quarters · filed 2026-08-10 | -$23.74M 10-Q · filed 2025-11-06 | $23.35M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $7.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $24.28M 10-Q · filed 2026-08-10 | $71.37M derived: sum of 3 quarters · filed 2026-08-10 | $113.15M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $16.60M 10-Q · filed 2026-05-11 | $63.69M derived: sum of 2 quarters · filed 2026-05-11 | $105.47M derived: sum of 3 quarters · filed 2026-05-11 | $111.28M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $47.09M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $88.86M derived: sum of 2 quarters · filed 2026-03-03 | $94.68M derived: sum of 3 quarters · filed 2026-03-03 | $17.45M 10-K · filed 2026-03-03 |
| 2024-09-30 | $41.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $47.59M derived: sum of 2 quarters · filed 2025-11-06 | -$29.64M 10-Q · filed 2025-11-06 | -$14.32M derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-06-30 | $5.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | -$71.41M 10-Q · filed 2025-08-11 | -$56.10M derived: sum of 3 quarters · filed 2026-03-03 | -$4.75M derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-03-31 | -$77.23M 10-Q · filed 2025-05-08 | -$61.92M derived: sum of 2 quarters · filed 2026-03-03 | -$10.57M derived: sum of 3 quarters · filed 2026-03-03 | $32.06M derived: sum of 4 quarters · filed 2026-03-03 |
| 2023-12-31 | $15.31M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $66.66M derived: sum of 2 quarters · filed 2026-03-03 | $109.28M derived: sum of 3 quarters · filed 2026-03-03 | $172.01M 10-K · filed 2026-03-03 |
| 2023-09-30 | $51.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $93.97M derived: sum of 2 quarters · filed 2024-11-08 | $156.70M 10-Q · filed 2024-11-08 | $245.13M derived: sum of 4 quarters · filed 2025-03-17 |
| 2023-06-30 | $42.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $105.35M 10-Q · filed 2024-08-08 | $193.78M derived: sum of 3 quarters · filed 2025-03-17 | $225.64M derived: sum of 4 quarters · filed 2025-03-17 |
| 2023-03-31 | $62.73M 10-Q · filed 2024-05-08 | $151.16M derived: sum of 2 quarters · filed 2025-03-17 | $183.01M derived: sum of 3 quarters · filed 2025-03-17 | $260.74M derived: sum of 4 quarters · filed 2025-03-17 |
| 2022-12-31 | $88.43M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $120.29M derived: sum of 2 quarters · filed 2025-03-17 | $198.02M derived: sum of 3 quarters · filed 2025-03-17 | $210.56M 10-K · filed 2025-03-17 |
| 2022-09-30 | $31.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $109.59M derived: sum of 2 quarters · filed 2023-11-08 | $122.13M 10-Q · filed 2023-11-08 | $48.47M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $77.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $90.28M 10-Q · filed 2023-08-03 | $16.61M derived: sum of 3 quarters · filed 2024-02-29 | -$169.29M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $12.54M 10-Q · filed 2023-05-08 | -$61.12M derived: sum of 2 quarters · filed 2024-02-29 | -$247.02M derived: sum of 3 quarters · filed 2024-02-29 | -$282.34M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | -$73.66M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$259.56M derived: sum of 2 quarters · filed 2024-02-29 | -$294.89M derived: sum of 3 quarters · filed 2024-02-29 | -$245.80M 10-K · filed 2024-02-29 |
| 2021-09-30 | -$185.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | -$221.23M derived: sum of 2 quarters · filed 2022-11-02 | -$172.14M 10-Q · filed 2022-11-02 | -$159.10M derived: sum of 4 quarters · filed 2023-03-16 |
| 2021-06-30 | -$35.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $13.77M 10-Q · filed 2022-08-04 | $26.81M derived: sum of 3 quarters · filed 2023-03-16 | -$241.50M derived: sum of 4 quarters · filed 2023-03-16 |
| 2021-03-31 | $49.09M 10-Q · filed 2022-05-10 | $62.13M derived: sum of 2 quarters · filed 2023-03-16 | -$206.18M derived: sum of 3 quarters · filed 2023-03-16 | -$242.65M derived: sum of 4 quarters · filed 2023-03-16 |
| 2020-12-31 | $13.04M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | -$255.27M derived: sum of 2 quarters · filed 2023-03-16 | -$291.74M derived: sum of 3 quarters · filed 2023-03-16 | -$252.56M 10-K · filed 2023-03-16 |
| 2020-09-30 | -$268.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | -$304.79M derived: sum of 2 quarters · filed 2021-11-08 | -$265.60M 10-Q · filed 2021-11-08 | |
| 2020-06-30 | -$36.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $2.71M 10-Q · filed 2021-08-04 | ||
| 2020-03-31 | $39.18M 10-Q · filed 2021-05-05 | |||
| 2019-12-31 | -$87.86M 10-K · filed 2022-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |